A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC by Wenbin Xiao, Valentina Nardi, Eytan Stein, Robert P. Hasserjian

Get full text

P441: CLINICAL AND MOLECULAR CHARACTERISTICS OF AML PATIENTS WITH AN EXCEPTIONAL RESPONSE TO IVOSIDENIB by Justin M. Watts, Prapti A Patel, Sung Choe, Xiaofei Bai, Dylan M Marchione, Eytan Stein

Get full text

P541: REAL-WORLD USE OF VENETOCLAX (VEN) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) IN A US REAL-WORLD EVIDENCE DATABASE (COTA) by Amer M. Zeidan, Leyla Hernandez- Donoso, Sejla Hodzic, Henry Owusu, Dhrubajyoti Pathak, Summera Zhou, Eytan Stein

Get full text

PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB... by Anand Patel, Laura Michaelis, Gary Schiller, Ronan Swords, Lawrence E. Morris, Luis A. Carvajal, Gordon Bray, Elizabeth A. Olek, Richard Cutler, Jorge Dimartino, Eytan Stein

Get full text

PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY by Stéphane de Botton, Thomas Cluzeau, Carlos Vigil, Rachel Cook, Philippe Rousselot, David Rizzieri, Jane Liesveld, Pierre Fenaux, Thorsten Braun, Arnaud Pigneux, Pierre Peterlin, Sofia Paul, Nisha Rajagopal, John Carulli, David Roth, Angela Volkert, Tanya Abdul Malak, Michael Kelly, Virginia Klimek, Eytan Stein

Get full text